How Eurofarma Cracked Brazil
This article was originally published in Scrip
Executive Summary
Firms that want to succeed in Brazil could learn a few things from Eurofarma, the country's fourth biggest company. A very big and highly prized sales force, large reinvestments and a broad portfolio are some of the reasons behind the home grown firm's success, explained Martha Novelli Penna, vice-president of strategy and innovation, and Maria del Pilar, director of sustainability and new business. And now with Brazil sewn up, the company is focusing on conquering the rest of Latin America.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.